Medication adherence is a fundamental consideration in one biopharmaceutical firm’s decision on whether to increase access to a cholesterol drug. Amgen, Inc. recently announced that increased access to Repatha would hinge on improving patients’ proper use of the medication.

RxAnte CEO Josh Benner weighed in on the news, encouraging Amgen to also work with physicians to improve adherence rates: “Adherence really starts in the office where the patient hears about the therapy along with the consequences of not taking it.”

Read the full article and find additional insights on BioCentury here.